Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cevostamab · BFCR-4350A, RO-7187797

Bispecific antibody · Immune activation, directed at Fc receptor-like protein 5 (FCRL5) and CD3 (CD3E) · developed by Genentech

Phase 1 Most advanced trial
1 Registered trials

What is Cevostamab?

Cevostamab is a bispecific T-cell engager antibody built from two single-chain variable fragments, one binding FCRH5 on tumor cells and one binding CD3 on cytotoxic T lymphocytes. By crosslinking these cells it triggers T-cell-mediated killing of FCRH5-expressing cells and is studied in multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BFCR-4350A, RO-7187797
Drug type
Bispecific antibody
Targets
Fc receptor-like protein 5 (FCRL5), CD3 (CD3E)
Mechanism
Immune activation, directed at Fc receptor-like protein 5 (FCRL5) and CD3 (CD3E)
Pathways
T-cell activation and crosslinking, CTL-mediated tumor cell death
Therapy area
Oncology
Developer
Genentech, Inc.
In trials of
REGN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
P86BHN01VE

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05137054 Phase 1 Multiple Myeloma Recruiting REGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Myeloma

Other drugs acting on FCRL5 / CD3E

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.